IBM Watson, Celgene partner for drug safety decision support platform

IBM Watson Health is working with the biopharmaceutical company Celgene to develop a drug safety project, according to Fortune.

The project, a drug safety decision support platform called "Watson for Patient Safety," will evaluate drugs before and after they are released into the market. The artificial intelligence platform will analyze claims data, medical records and individual case safety reports submitted to the FDA to identify complications or side effects early in the drug release process. This project is a complicated undertaking, according to Fortune, in part because individuals metabolize and react to drugs in different ways.

The ultimate goal of "Watson for Patient Safety" is to increase the number of safe, low-cost medical drugs on the market.

More articles on health IT:
75% of global internet use to be accessed through mobile devices in 2017: 5 things to know
Australian Red Cross reports data breach affecting 550k blood donors
56.3% of physicians in Arizona send patient information electronically: 5 ways EHR use varies by state

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.